StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
12
Publishing Date
2023 - 05 - 31
1
2021 - 01 - 28
1
2021 - 01 - 27
1
2020 - 12 - 22
2
2020 - 12 - 21
1
2020 - 12 - 18
1
2020 - 12 - 17
1
2020 - 12 - 15
1
2020 - 12 - 03
2
2020 - 12 - 02
1
Sector
Health technology
12
Tags
Anavex
1
Anavex®2-73
1
Anemia
1
Application
2
Authorized
1
Calendar of events
1
Clearance
1
Company announcement
1
Dementia
1
Designation
1
Diabetes
1
Disease
2
Drug
2
Enroll
1
Eye
2
Eye disease
1
Fda
1
Fda clearance
1
Fibrosis
1
Food
1
Gene therapies
1
Gene therapy
1
Glioblastoma
1
Health
1
Insulin
1
License
1
Life science
1
Macular
1
N/a
9
New drug
1
Ntla-2002
1
Obesity
1
Ongoing
1
Oxbryta
1
Oxytocin
1
Phase 1
1
Phase 2
3
Phase 3
2
Positive
2
Positive results
1
Potential
2
Psoriasis
1
Results
2
Rett syndrome
1
Study
1
Syndros
1
Therapeutics
1
Therapy
1
Treatment
9
Trial
2
Entities
Anavex life sciences corp.
1
Biocryst pharmaceuticals, inc.
1
Evelo biosciences, inc.
1
Eyepoint pharmaceuticals, inc.
1
Fibrogen, inc
1
Global blood therapeutics, inc.
1
Intellia therapeutics, inc.
1
Medicenna therapeutics corp.
1
Oyster point pharma, inc.
1
Passage bio, inc.
1
Sigilon therapeutics inc
1
Tonix pharmaceuticals holding corp.
1
Symbols
AVXL
1
BCRX
1
EVLO
1
EYPT
1
FGEN
1
GBT
1
MDNA
1
NTLA
1
OYST
1
PASG
1
SGTX
1
TNXP
1
Exchanges
Nasdaq
12
Crawled Date
2023 - 05 - 31
1
2021 - 01 - 28
1
2021 - 01 - 27
1
2020 - 12 - 22
2
2020 - 12 - 21
1
2020 - 12 - 18
1
2020 - 12 - 17
1
2020 - 12 - 15
1
2020 - 12 - 03
2
2020 - 12 - 02
1
Crawled Time
00:00
127
00:01
3
00:20
24
01:00
98
02:00
39
03:00
26
04:00
19
04:20
16
05:00
29
06:00
66
07:00
66
08:00
67
08:20
6
09:00
77
09:08
3
10:00
64
10:16
6
11:00
308
11:01
3
11:03
3
12:00
757
12:01
12
12:03
16
12:07
4
12:11
3
12:15
67
12:20
136
12:30
119
13:00
627
13:01
3
13:02
4
13:03
14
13:05
4
13:15
41
13:20
153
13:30
110
14:00
444
14:01
12
14:02
4
14:03
6
14:15
22
14:20
60
14:30
73
15:00
232
15:01
7
15:15
9
15:20
37
15:30
56
16:00
156
16:20
32
17:00
158
18:00
131
19:00
136
20:00
149
20:20
17
21:00
187
22:00
185
22:01
5
22:15
7
23:00
165
Source
www.globenewswire.com
12
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
treatment
crawled time :
12:01
save search
Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023
Published:
2023-05-31
(Crawled : 12:01)
- globenewswire.com
NTLA
|
$21.62
-0.87%
260K
|
Health Technology
|
-41.92%
|
O:
-0.75%
H:
3.7%
C:
-0.03%
ntla-2002
treatment
ongoing
therapeutics
study
Passage Bio Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations
Published:
2021-01-28
(Crawled : 12:01)
- globenewswire.com
PASG
|
$1.28
3.23%
30K
|
Health Technology
|
-93.69%
|
O:
2.09%
H:
3.24%
C:
-0.9%
gene therapy
therapy
fda clearance
treatment
fda
dementia
gene therapies
application
clearance
European Medicines Agency Accepts GBT’s Marketing Authorization Application (MAA) for Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Sickle Cell Disease
Published:
2021-01-27
(Crawled : 12:01)
- globenewswire.com
GBT
|
$68.49
0.02%
-0.02%
|
Health Technology
|
44.2%
|
O:
-0.51%
H:
11.09%
C:
7.51%
disease
treatment
anemia
oxbryta
authorized
application
Tonix Pharmaceuticals Acquires Exclusive License to University of Geneva Technology for Oxytocin-Based Treatments for Treating Insulin Resistance, Diabetes and Obesity, Expanding Proprietary Uses for TNX-1900 (Intranasal Potentiated Oxytocin)
Published:
2020-12-22
(Crawled : 12:01)
- globenewswire.com
TNXP
|
$0.1542
2.87%
1.5M
|
Health Technology
|
-73.71%
|
O:
3.05%
H:
1.28%
C:
-2.74%
diabetes
obesity
license
oxytocin
insulin
potential
FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2
Published:
2020-12-22
(Crawled : 12:01)
- globenewswire.com
FGEN
|
$1.3
650K
|
Health Technology
|
-96.75%
|
O:
0.67%
H:
1.22%
C:
0.42%
phase 3
treatment
fibrosis
BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva
Published:
2020-12-21
(Crawled : 12:01)
- globenewswire.com
BCRX
|
$4.66
1.09%
2.1M
|
Health Technology
|
-46.46%
|
O:
0.58%
H:
0.75%
C:
-4.16%
results
positive
treatment
phase 3
phase 1
phase 2
Oyster Point Pharma Submits New Drug Application to the U.S. Food and Drug Administration for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease
Published:
2020-12-18
(Crawled : 12:01)
- globenewswire.com
OYST
|
$11.17
0.18%
-0.27%
|
Health Technology
|
-45.42%
|
O:
1.57%
H:
0.55%
C:
-6.94%
disease
drug
eye disease
food
eye
new drug
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type I
Published:
2020-12-17
(Crawled : 12:01)
- globenewswire.com
SGTX
|
$22.47
-2.56%
0.0%
0
|
Health Technology
|
-22.97%
|
O:
0.37%
H:
10.23%
C:
9.28%
drug
treatment
designation
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome
Published:
2020-12-15
(Crawled : 12:01)
- globenewswire.com
AVXL
|
$4.11
-0.24%
450K
|
Health Technology
|
-20.62%
|
O:
20.42%
H:
2.08%
C:
-4.16%
life science
trial
phase 2
anavex®2-73
anavex
syndros
rett syndrome
Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of Psoriasis
Published:
2020-12-03
(Crawled : 12:01)
- globenewswire.com
EVLO
|
$0.3165
-87.39%
710K
|
Health Technology
|
-93.71%
|
O:
-0.6%
H:
4.0%
C:
0.4%
trial
treatment
phase 2
psoriasis
enroll
EyePoint Pharmaceuticals Reports Positive Results from GLP Toxicology Study of EYP-1901, a Potential Six-month Treatment of Wet Age-related Macular Degeneration
Published:
2020-12-03
(Crawled : 12:01)
- globenewswire.com
EYPT
|
$21.1
-3.39%
210K
|
Health Technology
|
312.08%
|
O:
-1.89%
H:
3.81%
C:
-1.1%
positive
results
positive results
eye
macular
treatment
potential
Medicenna Hosting Key Opinion Leader Call on MDNA55 for the Treatment of Recurrent Glioblastoma Multiforme
Published:
2020-12-02
(Crawled : 12:01)
- globenewswire.com
MDNA
|
$0.157
-0.32%
1.3M
|
Health Technology
|
-95.92%
|
O:
-1.04%
H:
3.67%
C:
3.29%
treatment
glioblastoma
Gainers vs Losers
63%
37%
Top 10 Gainers
INVO
|
$2.78
265.79%
200M
|
Health Technology
RYDE
|
$4.66
70.7%
410K
|
n/a
EDBL
|
$7.4
62.64%
12M
|
GRTX
|
$0.237
39.41%
13M
|
Health Technology
VNDA
|
$5.28
30.37%
21M
|
Health Technology
VIRX
|
$0.912
27.59%
170K
|
Manufacturing
WISA
4
|
$7.72
26.56%
51M
|
Electronic Technology
LUXH
|
$1.045
26.06%
540K
|
TCON
|
$2.135
24.85%
440K
|
Health Technology
AGFY
|
$0.37
24.2%
28M
|
Your saved searches
Save your searches and get alerts when important news are released.